You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Bone Health and Bone-Targeted Therapies for Prostate Cancer

Version: 2 ID: 3-14 sep 2016
Type of Content: Guidelines & Advice
Document Status: Current
S. Alibhai, K. Zukotynski, C. Walker-Dilks, U. Emmenegger, A. Finelli, S. Morgan, S. Hotte, E. Winquist

Guideline Objective

To evaluate the effectiveness of therapies targeting bone across all stages of prostate cancer

Patient Population

Men with prostate cancer

Intended Guideline Users

Healthcare professionals, health care administrators, medical or radiation oncologists who treat genitourinary cancer, urologists, radiologists, nuclear medicine physicians, geriatricians, primary care physicians, and osteoporosis experts.

Research Question(s)

  1. Can therapeutic interventions reduce osteoporosis-related outcomes in men with prostate cancer receiving androgen deprivation therapy (ADT)?
  2. Can therapeutic interventions prevent bone metastases in men with prostate cancer?
  3. Can bone-targeted therapies reduce the incidence of SREs, reduce pain, or improve quality of life in men with prostate cancer metastatic to bone?
  4. Can bone-targeted therapies improve overall survival in men with established prostate cancer and bone metastases?
pdf download Summary (PDF) (196.81 Ko)